Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

Launched by CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. ·

Keywords

ClinConnect Summary

This clinical trial is studying a new inhaled medicine called TQC3721 to see if it can help people with moderate to severe Chronic Obstructive Pulmonary Disease (COPD), a lung condition that makes it hard to breathe. The goal is to find out if this treatment can improve breathing and overall lung health in patients who have this condition.

The trial is open to adults of all genders who have moderate to severe COPD. While the study is not recruiting participants yet, those who join can expect to use the inhaled medicine and have their symptoms and lung function monitored over time. This is a Phase 3 trial, which means the treatment has already shown promise in earlier studies and is now being tested in a larger group to confirm its safety and effectiveness. If you or a loved one has COPD and are interested, it’s important to talk with your doctor to see if joining this study might be a good option.

Gender

ALL

Eligibility criteria